SoftBank-backed Neumora poised for Nasdaq debut after $250-mln IPO

Neumora Therapeutics

15/09/2023 10:06

** SoftBank-backed Neumora Therapeutics  NMRA.O  set to
begin trading on the Nasdaq later on Friday after raising $250
mln in its U.S. initial public offering 
    ** Co sold 14.7 million shares priced at the mid-point of
its previously disclosed range; IPO values Neumora at $2.58 bln 
    ** NMRA to start trading a day after SoftBank-owned chip
designer Arm Holdings soared in its market debut to notch a
valuation over $60 bln   
    ** "There’s growing hope that the IPO market will now become
more buoyant next year. IPO activity is a strong indicator of
overall sentiment," says Sophie Lund-Yates, lead equity analyst
at Hargreaves Lansdown
    ** J.P. Morgan, BofA Securities, Stifel, Guggenheim
Securities, RBC Capital Markets, and William Blair are acting as
joint book-running managers for NMRA's offering

 (Reporting by Manya Saini in Bengaluru)
 ((Manya.Saini@thomsonreuters.com))